[195 Pages Report] The Shingles Vaccine Market size was estimated at USD 1.73 billion in 2023 and expected to reach USD 1.87 billion in 2024, at a CAGR 8.11% to reach USD 2.99 billion by 2030.

The shingles vaccine market focuses on vaccines designed to prevent herpes zoster (shingles) and primarily targets adults aged 50 and above, as well as immunocompromised individuals. It encompasses various vaccines used to mitigate the severity and frequency of shingles, which is driven by factors such as the global aging population, increasing healthcare awareness, and supportive government initiatives. The market presents significant opportunities through technological advancements, geographical expansion, and strategic collaborations with local healthcare providers. However, challenges include high costs, limited awareness in certain regions, and stringent regulatory requirements which may delay vaccine approval and distribution. The market is dynamic and competitive, influenced by regulatory landscapes, healthcare policies, and emerging biotechnological trends. Companies should invest in research and development (R&D), establish strong distribution channels, and engage in public awareness campaigns to address cost barriers, enhance public knowledge, and seize growth opportunities.

The shingles vaccine market is strong in the United States, driven by significant healthcare expenditure, awareness programs, and an aging population. The Americas benefit from high healthcare standards and public health policies, led by the U.S. and Canada. EU countries such as Germany, and France show high adoption rates owing to government funding and public health campaigns. The Middle East, including the UAE and Saudi Arabia, is emerging with improvements in healthcare infrastructure. Africa faces challenges, but South Africa demonstrates higher adoption rates due to better facilities and public health initiatives. Japan benefits from an established healthcare system and high vaccination awareness. China shows significant growth potential due to its large aging population and proactive public health measures. India’s evolving market is supported by increasing healthcare investments and awareness campaigns. Asia-Pacific regions have rising awareness and healthcare spending, with significant consumer needs driven by aging populations.

The market dynamics represent an ever-changing landscape of the Shingles Vaccine Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

• Market Drivers
  • Increasing prevalence of chronic diseases
  • Rising number of geriatric population worldwide
  • Rising awareness about shingles health risks and growing focus on immunization
• Market Restraints
  • High capital requirements for vaccine development
• Market Opportunities
  • Ongoing Research & development initiatives on shingles vaccines
  • Significantly increasing public health expenditure worldwide
• Market Challenges
  • Adverse effects associated with shingles vaccines

• Product: Rising significance of Shingrix for higher safety profile

  Shingrix is the most vital segment in the shingles vaccine market. Shingrix vaccine has gained widespread acceptance and preference due to its high efficacy rate. As a non-live, recombinant subunit adjuvanted vaccine, Shingrix is safe for immunocompromised patients, which is a critical factor for healthcare providers. Zostavax maintains a notable position in the shingles vaccine market, although there has been a shift in preference towards Shingrix. As a live attenuated vaccine, Zostavax is generally preferred for its single-dose regimen, simplifying the vaccination process. SkyZoster was introduced to offer a live attenuated variant similar to Zostavax but has observed limited adoption beyond certain geographies. There has been an increased emphasis on the global expansion of SkyZoster, particularly targeting markets where alternatives such as Shingrix and Zostavax have limited penetration.

• Type: Understanding the benefits of recombinant shingles vaccines

  Recombinant vaccines, such as Shingrix, have become the preferred choice for shingles prevention. Recombinant vaccines are designed using a piece of the virus’ protein, making them non-live and less prone to complications. Recombinant vaccines do not contain live viruses, which significantly reduces the risk of developing shingles from the vaccine itself. Live attenuated vaccines, such as Zostavax, have traditionally been used to prevent shingles. Live attenuated vaccines contain a weakened version of the varicella-zoster virus to stimulate an immune response.

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Shingles Vaccine Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Shingles Vaccine Market.

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Shingles Vaccine Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

The value chain of the Shingles Vaccine Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

The pricing analysis comprehensively evaluates how a product or service is priced within the Shingles Vaccine Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Shingles Vaccine Market.

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Shingles Vaccine Market.

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Shingles Vaccine Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

The trade analysis of the Shingles Vaccine Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

The regulatory framework analysis for the Shingles Vaccine Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Shingles Vaccine Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Shingles Vaccine Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

• Dynavax Begins Clinical Trial for Promising Shingles Vaccine, Z-1018

  Dynavax Technologies Corporation, which focuses on creating and marketing innovative vaccines, has commenced a Phase 1/2 clinical trial for its investigational shingles vaccine, Z-1018. The trial aims to evaluate the safety, tolerability, and immunogenicity of Z-1018, targeting the prevention of shingles, a condition caused by the varicella-zoster virus. Dosing the first participant marks a critical advancement in the vaccine's development. The anticipated results from this trial could significantly impact Dynavax's standing in the biopharmaceutical market and influence its long-term strategy. [Published On: 2024-06-27]

• Sinovac Biotech Ltd. Expands PROVARIX Vaccine Approval to Adolescents and Adults, Targeting Increased Public Health Benefits

  Sinovac Biotech Ltd has achieved regulatory approval from the China National Medical Products Administration (NMPA) for its PROVARIX vaccine for individuals aged 13 and above. This expansion into the adolescent and adult demographic, involving a two-dose regimen spaced 4 to 8 weeks apart, follows its prior approval for children aged 12 months to 12 years. This development is aimed at increasing market penetration and bolstering public health, paving the way for strategic growth and broader immunization coverage across various age groups. [Published On: 2024-06-18]

• GSK Expands Shingrix Vaccine Approval to Younger Adults in China, Targets Broader Public Health Impact

  GSK plc's announcement underscores a significant advancement as the Center for Drug Evaluation of the China National Medical Products Administration accepted the regulatory application for Shingrix (Recombinant Zoster Vaccine or RZV) aimed at preventing shingles in adults aged 18 and over at increased risk. Initially approved in 2019 for adults 50+, GSK's Shingrix targets a broader age group, reflecting its adaptability and potential to address a wider public health need. [Published On: 2024-02-06]

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Shingles Vaccine Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

The report delves into recent significant developments in the Shingles Vaccine Market, highlighting leading vendors and their innovative profiles. These include CSL Limited, Biogenetech Co., Ltd., Gilead Sciences, Inc., Barinthus Biotherapeutics plc, Bavarian Nordic, Daiichi Sankyo Company, Limited, GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., SK Chemicals, Pfizer Inc., GeneOne Life Science, Inc., CanSino Biologics Inc., Astellas Pharma Inc., Jiangsu Recbio Technology Co., Ltd., Curevo Inc., Sanofi S.A., Valneva SE, JCR Pharmaceuticals Co., Ltd., Merck KGaA, Sinovac Biotech Ltd., VBI Vaccines Inc., Emergent Biosolutions Inc., Takeda Pharmaceutical Company Limited, Moderna, Inc., and Dynavax Technologies Corporation.

This research report categorizes the Shingles Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • SkyZoster
  • Zostavax
  • ​​Shingrix
• Type
  • Live Attenuated Vaccine
  • Recombinant Vaccine
• Distribution Channel
  • Healthcare Centers
  • Pharmacies

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

1. What is the current market size and projected growth?
2. Which products, segments, applications, and regions offer promising investment opportunities?
3. What are the prevailing technology trends and regulatory frameworks?
4. What is the market share and positioning of the leading vendors?
5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?